Group K Diagnostics and Health Network agree to start clinical trials

Biotechnology firm Group K Diagnostics (GKD) and laboratory medicine services provider Health Network Laboratories (HNL) have partnered on a clinical trial agreement to bring improved clinical experiences to patients and caregivers.

Patients looking for liver function testing will be able to participate in a clinical trial using GKD’s microfluidic point-of-care device MultiNostic.

The technology is said to provide accurate results in 20 minutes using blood from only a simple finger stick.

GKD CEO and founder Brianna Wronko said: “This collaboration is another step in our work to bring an improved clinical experience to more people.

“HNL is just as committed to this objective, and we are so thrilled to have the opportunity to bring truly cutting-edge technology to the Lehigh Valley community.”

The clinical trial will prove the accuracy and efficacy of the MultiNostic device and analyse the impact on operational efficiencies, as well as the resulting clinical implications.

Patients will receive appropriate care using the device, reducing the extent of the administrative functions of the care providers.

HNL acting CEO and president Matt Sorrentino said: “Typical clinical trials for medical devices focus on producing data. Although important, this single focus overlooks the operational influence of the technology.

“In working with GKD, HNL continues its legacy of innovation. This latest technology advancement may transform how and where certain diagnostic tests are performed.”

Patients aged 18 years or older can sign up at two of HNL’s Patient Service Centers to enrol in the free clinical trial.

The company noted that the Patient Service Centers participating in the trial are located at 1630 N Cedar Crest Boulevard and 3219-B Schoenersville Road and Avenue C.